---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020543"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T13:44:24.699554+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CFO Jeffrey Church retiring June 1; David Gaiero appointed as successor

## Summary
- Jeffrey Church to retire as CFO effective June 1, 2024; will serve as consultant through Dec 31, 2024.
- Church receives retirement bonus of $428,615; monthly consulting retainer of $10,000 plus $250/hr over 40 hrs.
- David Gaiero appointed CFO via Monomoy Advisors; monthly fee of $35,000 starting June 1, 2024.
- Gaiero is a partner at Monomoy, served as CFO of Cyteir Therapeutics and interim CFO at Wave Life Sciences.
- Church's vested stock options extended to original expiration; unvested options treated per plan.

## SEC filing metadata
- accession: 0001493152-24-020543
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020543
- JSON: https://secwatch.observer/filing/0001493152-24-020543.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020543.txt

## Key facts
- Executive change
  Jeffrey Church retired as Chief Financial Officer at Imunon, Inc..
  - Action: retired
  - Role: Chief Financial Officer
  source text: On May 15, 2024, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from all positions with the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm
- Executive change
  David Gaiero was appointed as Chief Financial Officer at Imunon, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: effective June 1, 2024, the Company appointed David Gaiero to serve as the Company’s new Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.